How effective is Xopenex for Chronic Obstructive Pulmonary Disease? (a real world drug study)
Summary:
Overall ratings: 3.4/5 Long term ratings: 3.5/5
This is a phase IV clinical study of how effective Xopenex (levalbuterol hydrochloride) is for Chronic obstructive pulmonary disease and for what kind of people. The study is created by eHealthMe from 25 Xopenex users and is updated continuously.
What is Xopenex?
Xopenex has active ingredients of levalbuterol hydrochloride. It is often used in asthma. eHealthMe is studying from 13,816 Xopenex users. Check the latest studies of Xopenex.
What is Chronic obstructive pulmonary disease?
Chronic obstructive pulmonary disease (a progressive disease that makes it hard to breathe) is found to be associated with 1,801 drugs and 2,209 conditions by eHealthMe. Check the latest studies of Chronic obstructive pulmonary disease.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
25 people are studied for taking Xopenex in Chronic obstructive pulmonary disease
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Xopenex effectiveness for Chronic obstructive pulmonary disease (number of people):
Overall:
- not at all: 0
- somewhat: 5
- moderate: 8
- high: 10
- very high: 2
Long Term:
- not at all: 0
- somewhat: 2
- moderate: 7
- high: 6
- very high: 2
Gender of people who take Xopenex for Chronic obstructive pulmonary disease *:
- female: 80 %
- male: 20 %
Age of people who take Xopenex for Chronic obstructive pulmonary disease *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 4 %
- 40-49: 8 %
- 50-59: 24 %
- 60+: 64 %
Who find Xopenex more effective for Chronic Obstructive Pulmonary Disease?
Gender of people who take Xopenex for Chronic obstructive pulmonary disease *:
- female: 83.33 %
- male: 16.67 %
Age of people who take Xopenex for Chronic obstructive pulmonary disease *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 8.33 %
- 40-49: 8.33 %
- 50-59: 41.67 %
- 60+: 41.67 %
* Approximation only. Some reports may have incomplete information.
Do you take Xopenex?
- You can start a phase IV clinical trial to monitor Xopenex safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related studies
Alternative drugs to, pros and cons of:
- Xopenex (13,816 reports)
Treatments, associated drugs and conditions:
- Chronic obstructive pulmonary disease (198,253 reports)
How the study uses the data?
The study is based on levalbuterol hydrochloride (the active ingredients of Xopenex) and Xopenex (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Allopurinol cause Renal Failure Chronic Aggravated? - a second ago
- Diabetes and Visual Impairment - 3 seconds ago
- Could Aranesp cause Haemolysis? - 5 seconds ago
- Chloraprep One-Step and Arava drug interactions for women aged 40-49 - 18 seconds ago
- Could Viibryd cause Head Injury? - 18 seconds ago
- Insulin Nordisk Mixtard vs. Amaryl, side effect and effectiveness comparison - 19 seconds ago
- Could Dapagliflozin cause Chest Pain? - 20 seconds ago
- Could Creon cause Jaundice - Yellow Skin? - 22 seconds ago
- Cosentyx and Wasting for Women aged 50-59 - 27 seconds ago
- Cosentyx and Muscle Wasting for Women aged 50-59 - 28 seconds ago